Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model

• Main Authors: Yuki Narita (Author), Miki Ueda (Author), Kohei Uchimura (Author), Yutaka Kakizoe (Author), Yoshikazu Miyasato (Author), Teruhiko Mizumoto (Author), Jun Morinaga (Author), Manabu Hayata (Author), Terumasa Nakagawa (Author), Masataka Adachi (Author), Taku Miyoshi (Author), Yoshiki Sakai (Author), Daisuke Kadowaki (Author), Sumio Hirata (Author), Masashi Mukoyama (Author), Kenichiro Kitamura (Author)
• Format: Book
• Published: Elsevier, 2016-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We previously reported that camostat mesilate (CM) had renoprotective and antihypertensive effects in rat CKD models. In this study, we examined if CM has a distinct renoprotective effect from telmisartan (TE), a renin-angiotensin-aldosterone system (RAS) inhibitor, on the progression of CKD. We eva...